The Morgan Stanley Reiterates €20.00 Price Target for Orange SA (ORA)

Finally, UBS AG set a €50.00 ($57.47) price target on shares of Total SA and gave the stock a "neutral" rating in a report on Tuesday, July 4th. The correct version of this piece can be viewed at https://sportsperspectives.com/2017/07/18/total-sa-fp-receives-average-rating-of-buy-from-brokerages-updated-updated.html. Deutsche Bank AG set a €17.40 ($20.00) price target on Orange SA and gave the company a buy rating in a report on Friday, February 24th. Morgan Stanley set a €47.50 ($54.60) price target on shares of Total SA and gave the stock a "neutral" rating in a report on Monday. Finally, Morgan Stanley set a €50.00 ($57.47) price objective on shares of Total SA and gave the company a neutral rating in a report on Monday, April 24th.

Shares of Sanofi SA (EPA:SAN) have been given an average recommendation of "Hold" by the seventeen research firms that are presently covering the stock, Marketbeat reports. J P Morgan Chase & Co set a €95.00 ($109.20) price target on shares of Sanofi SA and gave the company a "neutral" rating in a research report on Thursday, June 22nd. Two analysts have rated the stock with a sell recommendation, ten have given a hold recommendation and five have given a buy recommendation to the company.

Sanofi SA (EPA SAN) opened at 84.28 on Tuesday.

COPYRIGHT VIOLATION WARNING: "Orange SA (ORA) Given a €19.00 Price Target by Goldman Sachs Group, Inc". Total SA has a 12-month low of €40.53 and a 12-month high of €49.50. The average 12-month target price among analysts that have issued a report on the stock in the previous year is €50.80 ($58.39). The firm has a market capitalization of €38.03 billion and a P/E ratio of 13.785. If you are reading this piece on another domain, it was illegally copied and reposted in violation of United States and global copyright and trademark legislation. The firm's 50-day moving average price is €46.35 and its 200-day moving average price is €47.31. The Pharmaceuticals segment comprises the commercial operations of various franchises, including Speciality Care (Rare Diseases, Multiple Sclerosis, and Oncology), Diabetes and Cardiovascular, Established Prescription Products, Consumer Healthcare and Generics, and research and development, production and marketing activities for all of the Company's pharmaceuticals operations.

Notícias recomendadas

We are pleased to provide this opportunity to share information, experiences and observations about what's in the news.
Some of the comments may be reprinted elsewhere in the site or in the newspaper.
Thank you for taking the time to offer your thoughts.